ClinicalTrials.gg
CompletedNCT06563102DARWINUpdated Feb 27, 2026

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

A Phase 4 interventional study of Albuterol/Budesonide and Albuterol in Mild Asthma, sponsored by AstraZeneca. Completed at 16 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionAsthmaRegistry: Respiratory HypersensitivityReclassifiedWhy we changed it
Registry
Respiratory Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Asthma
Why
  1. The study's listed conditions name Asthma, a narrower term within Respiratory Hypersensitivity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Enrollment
23rd of 72
101 · median 63
Started
2024
with 8 others
Phase 4
25 of 72
2 open now
Registered
67th of 72
by date
Lead sponsor
4 of 72
AstraZeneca

Among the 72 studies testing albuterol in Asthma, this one is the 23rd largest by enrollment, is one of 9 that started in 2024, is one of 25 in phase 4, and was the 67th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma.

Study details include:

  • The study duration will be up to 15 weeks.
  • The treatment duration will be 12 weeks.
  • The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Read the detailed description

DARWIN is a randomized, active-comparator, double-blind, parallel-group, Phase IV study evaluating the effect of albuterol/budesonide (AIRSUPRA) compared to albuterol administered as-needed in response to symptoms on changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma.

Approximately 15 sites in the United States of America will enroll adult participants with mild asthma who use albuterol as a rescue inhaler and who do not take ICS as maintenance therapy.

The study will be divided in 2 periods (Lead-in Period and Treatment Period) and the total duration of the study for each participant could be up to 15 weeks, with a visit frequency of once every 4 weeks:

  • Lead-In Period: Up to 3 weeks
  • Treatment Period: 12 weeks
03

Conditions studied

  • Mild Asthma

Browse trials for

Keywords

  • Respiratory Hypersensitivity
  • Asthma
04

In context

Asthma Reclassified

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

This study's enrollment of 101 is above the median of 79 across 3,344 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Asthma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1 Capable of giving signed informed consent as described in the protocol which included compliance with the requirements and restrictions listed in the ICF and protocol

Type of Participant and Disease Characteristics 3 Diagnosis of asthma, by a prescribing health care professional 4 ≥ 2 prescriptions for a SABA inhaler in the past 12 months prior to Visit 1 (and the expectation that the participant will probably use their rescue inhaler ≥ 2 days per week as this is required at Visit 2 for randomization following the Lead-in Period) 5 FeNO ≥ 25 ppb at Visit 1

Sex and /Barrier Requirements 7 Female participants: Females must be not of or using a form of birth control as defined below:

  • Females not of childbearing potential are defined as females who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . The following age-specific requirements apply:

    • Females \< 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and in the absence of any alternative medical cause, as judged by the investigator.
    • Females ≥ 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  • Female participants of childbearing potential must use a highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Females of childbearing potential who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 14 days after last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

    • All females of childbearing potential must have a negative pregnancy test result at Visit 1.
    • Females \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and in the absence of any alternative medical cause, as judged by the investigator.
  • Highly effective birth control methods are listed below:

    • Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).
    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
  • Oral
  • Intravaginal
  • Transdermal

    • Progestogen-only hormonal contraception associated with inhibition of ovulation:
  • Oral
  • Injectable
  • Implantable

    • Intrauterine device or intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Male partner sterilization/vasectomy with documentation of azoospermia prior to the female participant's entry into the study, and this male is the sole partner for that participant. The documentation on male sterility can come from the site personnel's review of participant's medical records, medical examination and/or semen analysis or medical history interview provided by her or her partner.

      8 Negative pregnancy test (urine) for female participants of childbearing potential at Visit 1.

Randomization Criteria 5.1.1 at Visit 2 (Week 0)

  1. Symptoms requiring rescue medication use for a minimum of 2 days per week for the last 14 days during the Lead-in Period (minimum 4 uses total)
  2. At least 80% overall compliance rate for performing daily FeNO and spirometry assessments and completing the twice-daily asthma symptom and rescue medication use diary during the Lead-in Period.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Any significant disease or disorder, or evidence of drug/substance abuse which in the investigator's opinion would pose a risk to participant safety, interfere with the conduct of study, have an impact on the study results, or make it undesirable for the participant to participate in the study.
  2. Medical history of life-threatening asthma including intubation and intensive care unit admission.
  3. Medical conditions (other than allergic rhinitis) or medications that will influence FeNO, as judged by the investigator.
  4. Concurrent respiratory disease: presence of a known pre-existing, lung condition other than asthma (eg, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, ).
  5. Any disease state or procedure that is likely to necessitate the use of oral/systemic during the Treatment Period, other than asthma.
  6. : a current malignancy or previous history of cancer in remission for less than 12 months prior to Visit 1 (participants with treated localized squamous cell or basal cell carcinoma of the skin will not be excluded, whereas participants who had melanoma will be excluded). Participants with a history/treatment of malignancy, and which in the investigator's opinion could compromise the safety of the participant.
  7. Other concurrent medical conditions: participants who have known, pre-existing, clinically significant cardiovascular (including clinically significant cardiac arrhythmia and participants with known corrected for heart rate using the Fridericia formula > 480 ms), endocrine, , metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment.
  8. Current smokers: previous smokers are allowed to be included provided that they stopped smoking > 12 months prior to Visit 1 AND have a smoking history of ≤ 10 pack-years (includes tobacco, e-cigarettes, vapes, marijuana, etc.).
  9. Alcohol/substance abuse: a history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Visit 1.

    Prior/Concomitant Therapy

  10. Use of ICS-containing therapy for maintenance or rescue at enrolment. Other therapies for maintenance of asthma control are allowed (leukotriene receptor antagonists and/or antihistamines, for example), but not LAMA or LABA.
  11. Use of any systemic or inhaled corticosteroid within 4 weeks of Visit 1
  12. Planned use of a nebulizer during the study (between Visits 1 and 5)

    Prior/Concurrent Clinical Study Experience

  13. Participation in another clinical study with any marketed or anti-allergic or biologic drug within 4 months or 5 half-lives (whichever is longer) prior to Visit 1.
  14. Participation in another clinical study with a non-biologic investigational product or new formulation of a marketed non-biologic drug during the last 30 days prior to Visit 1.

    Other Exclusions

  15. Participants with a known to the study drugs or any of the of the products.
  16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  17. Previous randomization in the present study.
  18. For women only: currently pregnant (confirmed with positive pregnancy test), breastfeeding or planned pregnancy during the study.
  19. Planned hospitalization during the study that would interfere with study objectives as judged by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Group 1 - Participants randomized to receive albuterol/budesonide

    Participants will be randomized based on Visit 1 FeNO levels (\< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed rescue therapy.

    Combination Product: Albuterol/Budesonide

  • Active comparator
    Group 2 - Participants randomized to receive albuterol

    Participants will be randomized based on Visit 1 FeNO levels (\< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed rescue therapy.

    Combination Product: Albuterol

Interventions

  • Combination productAlbuterol/Budesonide

    Drug pages: Albuterol · Budesonide

    Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation

    Also known as: AIRSUPRA, BDA MDI HFA

  • Combination productAlbuterol

    Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.

    Also known as: AS MDI

07

What researchers measure

Primary outcomes

  1. Change from baseline to maximum value of daily morning FeNO

    Change from baseline to maximum value of daily morning FeNO over 12 weeks of treatment in the albuterol/budesonide group compared to the albuterol group.

    Time frame: Daily over 12 weeks

Secondary outcomes

  1. Change from baseline in FeNO on high inflammation days

    Change from baseline in FeNO on high inflammation days in the albuterol/budesonide group compared to the albuterol group. A high inflammation day is a day in which the FeNO value is ≥ 20 ppb above baseline.

    Time frame: Daily over 12 weeks

  2. Number of days with high inflammation (annualized rate)

    Number of days with high inflammation in the albuterol/budesonide group compared to the albuterol group. A high inflammation day is a day in which the FeNO value is ≥ 20 ppb above baseline.

    Time frame: Daily over 12 weeks

  3. Number of days with daily morning FeNO measurements ≥ 50 ppb (annualized rate)

    Number of days with FeNO \>= 50 ppb in the albuterol/budesonide group compared to the albuterol group.

    Time frame: Daily over 12 weeks

  4. Number of days with daily morning FeNO measurements ≥ 25 ppb (annualized rate)

    Number of days with FeNO \>= 25 ppb in the albuterol/budesonide group compared to the albuterol group.

    Time frame: Daily over 12 weeks

  5. Mean absolute difference in daily morning FeNO over 12 weeks of randomized treatment

    Mean daily change in FeNO from the median of the individual's daily FeNO measures over 12 weeks in the albuterol/budesonide group compared to the albuterol group.

    Time frame: Daily over 12 weeks

Other outcomes

  1. Number of SAEs and DAEs

    Evaluate the safety and tolerability of albuterol/budesonide compared to albuterol in patients with asthma.

    Time frame: Week 12

08

Study locations

16 sites
  • Research Site
    Phoenix, Arizona 85040, United States
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Cape Coral, Florida 33990, United States
  • Research Site
    Lake Worth, Florida 33462, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Boise, Idaho 83706, United States
  • Research Site
    Plainfield, Indiana 46168, United States
  • Research Site
    St Louis, Missouri 63141, United States
  • Research Site
    Riverdale, New Jersey 07457, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    North Charleston, South Carolina 29420, United States
  • Research Site
    El Paso, Texas 79903, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Waco, Texas 76712, United States
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPI/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Feb 2026, 17 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 17 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 20, 2024
StartActual
Sep 11, 2024
Primary completionActual
Feb 24, 2026
CompletionActual
Feb 24, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06563102
Lead sponsor
AstraZeneca
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Sep 11, 2024
Primary completion
Feb 24, 2026
Completion
Feb 24, 2026
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albuterol · Budesonide

Start the discussion